======= APOC3 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: APOC3
  * **<color #00a2e8>Official Name</color>**: apolipoprotein C3
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=345|345]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/P02656|P02656]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=APOC3&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20APOC3|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/107720|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  This gene encodes a protein component of triglyceride (TG)-rich lipoproteins (TRLs) including very low density lipoproteins (VLDL), high density lipoproteins (HDL) and chylomicrons. The encoded protein plays a role in role in the metabolism of these TRLs through multiple modes. This protein has been shown to promote the secretion of VLDL1, inhibit lipoprotein lipase enzyme activity, and delay catabolism of TRL remnants. Mutations in this gene are associated with low plasma triglyceride levels and reduced risk of ischemic cardiovascular disease, and hyperalphalipoproteinemia, which is characterized by elevated levels of high density lipoprotein (HDL) and HDL cholesterol in human patients. This gene and other related genes comprise an apolipoprotein gene cluster on chromosome 11. [provided by RefSeq, Sep 2017]. 
  * **<color #00a2e8>UniProt Summary</color>**:  Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed:18201179, PubMed:22510806). Plays a multifaceted role in triglyceride homeostasis (PubMed:18201179, PubMed:22510806). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed:18201179, PubMed:22510806). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed:18201179, PubMed:22510806). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed:18408013). {ECO:0000269|PubMed:18408013, ECO:0000303|PubMed:18201179, ECO:0000303|PubMed:22510806}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|Apo-CIII|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|negative regulation of high-density lipoprotein particle clearance|
|negative regulation of sterol import|
|negative regulation of cholesterol import|
|high-density lipoprotein particle receptor binding|
|negative regulation of very-low-density lipoprotein particle remodeling|
|regulation of high-density lipoprotein particle clearance|
|regulation of sterol import|
|negative regulation of very-low-density lipoprotein particle clearance|
|regulation of cholesterol import|
|regulation of very-low-density lipoprotein particle clearance|
|negative regulation of triglyceride catabolic process|
|regulation of very-low-density lipoprotein particle remodeling|
|intermediate-density lipoprotein particle|
|negative regulation of low-density lipoprotein particle clearance|
|negative regulation of lipoprotein lipase activity|
|lipase inhibitor activity|
|regulation of Cdc42 protein signal transduction|
|triglyceride-rich lipoprotein particle clearance|
|negative regulation of lipoprotein particle clearance|
|chylomicron remnant clearance|
|spherical high-density lipoprotein particle|
|negative regulation of triglyceride metabolic process|
|chylomicron remodeling|
|chylomicron assembly|
|very-low-density lipoprotein particle assembly|
|regulation of low-density lipoprotein particle clearance|
|negative regulation of cholesterol transport|
|regulation of triglyceride catabolic process|
|phospholipid efflux|
|negative regulation of sterol transport|
|chylomicron|
|triglyceride-rich lipoprotein particle remodeling|
|negative regulation of fatty acid biosynthetic process|
|enzyme regulator activity|
|reverse cholesterol transport|
|negative regulation of lipase activity|
|high-density lipoprotein particle remodeling|
|regulation of lipoprotein particle clearance|
|very-low-density lipoprotein particle|
|regulation of lipoprotein lipase activity|
|negative regulation of receptor-mediated endocytosis|
|cholesterol efflux|
|negative regulation of lipid catabolic process|
|negative regulation of fatty acid metabolic process|
|negative regulation of lipid transport|
|plasma lipoprotein particle assembly|
|triglyceride catabolic process|
|protein-lipid complex remodeling|
|plasma lipoprotein particle remodeling|
|protein-containing complex remodeling|
|protein-lipid complex assembly|
|acylglycerol homeostasis|
|acylglycerol catabolic process|
|regulation of triglyceride metabolic process|
|triglyceride homeostasis|
|neutral lipid catabolic process|
|plasma lipoprotein particle clearance|
|negative regulation of lipid localization|
|negative regulation of endocytosis|
|plasma lipoprotein particle organization|
|regulation of fatty acid biosynthetic process|
|regulation of cholesterol transport|
|regulation of sterol transport|
|protein-lipid complex subunit organization|
|negative regulation of lipid biosynthetic process|
|cholesterol binding|
|glycerolipid catabolic process|
|cholesterol transport|
|regulation of lipid catabolic process|
|sterol transport|
|regulation of plasma lipoprotein particle levels|
|triglyceride metabolic process|
|cholesterol homeostasis|
|sterol homeostasis|
|negative regulation of lipid metabolic process|
|regulation of fatty acid metabolic process|
|negative regulation of small molecule metabolic process|
|phospholipid transport|
|regulation of lipase activity|
|acylglycerol metabolic process|
|neutral lipid metabolic process|
|regulation of receptor-mediated endocytosis|
|retinoid metabolic process|
|phospholipid binding|
|regulation of lipid transport|
|diterpenoid metabolic process|
|lipoprotein metabolic process|
|terpenoid metabolic process|
|organophosphate ester transport|
|lipid homeostasis|
|organic hydroxy compound transport|
|isoprenoid metabolic process|
|regulation of lipid localization|
|regulation of Rho protein signal transduction|
|regulation of cellular ketone metabolic process|
|regulation of lipid biosynthetic process|
|cellular lipid catabolic process|
|regulation of endocytosis|
|regulation of Ras protein signal transduction|
|negative regulation of cellular catabolic process|
|early endosome|
|lipid transport|
|lipid catabolic process|
|negative regulation of catabolic process|
|lipid localization|
|regulation of small GTPase mediated signal transduction|
|collagen-containing extracellular matrix|
|glycerolipid metabolic process|
|extracellular structure organization|
|regulation of lipid metabolic process|
|regulation of small molecule metabolic process|
|negative regulation of hydrolase activity|
|organic anion transport|
|negative regulation of transport|
|regulation of vesicle-mediated transport|
|anion transport|
|negative regulation of cellular component organization|
|negative regulation of catalytic activity|
|regulation of cellular catabolic process|
|cellular lipid metabolic process|
|regulation of catabolic process|
|chemical homeostasis|
|negative regulation of molecular function|
|negative regulation of multicellular organismal process|
|lipid metabolic process|
|regulation of hydrolase activity|
|G protein-coupled receptor signaling pathway|
|ion transport|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|protein-containing complex assembly|
|extracellular space|
|homeostatic process|
|organic substance catabolic process|
|cellular catabolic process|
|regulation of intracellular signal transduction|
|protein-containing complex subunit organization|
|regulation of transport|
|extracellular region|
</modal>
\\

 === CRISPR Data ===
<button type='default' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
No hits were found.
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
No correlation found to any other genes in chemogenomics.
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 11614
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: -7.68 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='APOC3 Expression in NALM6 Cells: -7.68'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>